- Home
- FENC vs TLSI Comparison
FENC vs TLSI Comparison
Compare FENC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | TLSI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 270.2M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | FENC | TLSI |
|---|---|---|
| Price | $9.69 | $3.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.50 | $7.00 |
| AVG Volume (30 Days) | 257.1K | ★ 618.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | $35.45 |
| Revenue Next Year | $41.08 | $37.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $2.20 |
| 52 Week High | $10.27 | $7.95 |
Technical Indicators
Market Signals| Indicator | FENC | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 76.50 | 37.39 |
| Support Level | $7.45 | $2.20 |
| Resistance Level | $9.92 | $5.41 |
| Average True Range (ATR) | 0.61 | 0.34 |
| MACD | 0.35 | -0.14 |
| Stochastic Oscillator | 86.85 | 41.11 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.